RxElite, Inc. (RXEI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRxElite, Inc. (RXEI) trades at $0.0001. RxElite, Inc. specializes in the development, production, and commercialization of generic prescription drugs, focusing on sterile liquid dose offerings and active pharmaceutical ingredients (APIs). Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for RXEI: RXEI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
RxElite, Inc. (RXEI) Healthcare & Pipeline Overview
RxElite, Inc. specializes in developing, producing, and commercializing generic prescription drugs, particularly sterile liquid dose offerings like ophthalmic solutions, respiratory inhalants, and injectables. As a subsidiary of Piramal Healthcare Ltd., it also manufactures active pharmaceutical ingredients (APIs) for a global client base, serving hospitals, wholesalers, and retail pharmacies across specialty markets.
What Is the Investment Thesis for RXEI?
RxElite, Inc. operates within the specialized generic pharmaceutical market, focusing on high-demand sterile liquid dose products and active pharmaceutical ingredient (API) manufacturing. The company's diverse portfolio, encompassing generic ophthalmic solutions, respiratory inhalants, and injectables, targets critical healthcare needs across institutional and retail channels. Strategic alliances with partners like Stason Pharmaceuticals and Alkem Laboratories enhance its market reach and development capabilities, while its role as an API manufacturer provides a diversified revenue stream across the US, Europe, and Asia. However, the company faces significant financial challenges, evidenced by a negative profit margin of -610.5% and a low gross margin of 5.1%. Its listing on the 'OTC Other' tier suggests higher risk due to potential limited disclosure and lower liquidity. Investors should evaluate RxElite's ability to achieve sustainable profitability and navigate regulatory complexities within the highly competitive generic drug sector, while also considering the strategic value derived from its specialized product focus and parent company affiliation.
Based on FMP financials and quantitative analysis
RXEI Key Highlights
RxElite, Inc. reported a negative profit margin of -610.5%, indicating substantial unprofitability within its operations.
- The company maintains a gross margin of 5.1%, reflecting a narrow profit after accounting for the cost of goods sold.
- With a Beta of 6.40, RxElite, Inc. exhibits extremely high volatility relative to the broader market, suggesting significant price fluctuations.
- RxElite, Inc. operates with 47 employees, focusing on specialized generic drug development and API manufacturing.
- The company is a subsidiary of Piramal Healthcare Ltd., leveraging a larger corporate structure for its operations and strategic direction.
Who Are RXEI's Competitors?
RXEI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RXEI's Key Strengths?
Specialization in sterile liquid dose generic drugs, addressing niche and high-demand markets.
- Diverse product portfolio including ophthalmic, respiratory, and injectable medications.
- Dual revenue streams from finished drug products and active pharmaceutical ingredient (API) manufacturing.
- Extensive customer base across institutional, wholesale, retail, and outpatient sectors.
- Strategic alliances with established industry partners enhancing market reach and capabilities.
What Are RXEI's Weaknesses?
Significant unprofitability with a negative profit margin of -610.5%.
- Low gross margin of 5.1%, indicating limited profitability from core sales.
- Listing on the 'OTC Other' tier, implying higher risk and potentially limited transparency.
- Unknown disclosure status, which can hinder investor due diligence.
- Operating as a subsidiary, which may limit independent strategic decision-making.
What Are the Key Risks for RXEI?
Financial-distress signal — its Altman Z-Score of -2.08 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Sustained unprofitability, as indicated by a negative profit margin of -610.5%, posing challenges to long-term financial viability.
- Operating on the 'OTC Other' tier, which typically implies higher risk due to limited disclosure, lower liquidity, and increased price volatility.
- Intense competition within the generic drug and API manufacturing sectors, leading to pricing pressures and market share erosion.
- Regulatory compliance challenges and the need for continuous adherence to evolving pharmaceutical industry standards.
- Dependence on strategic alliances, where changes in partner relationships or performance could impact business operations and growth opportunities.
What Threats Does RXEI Face?
- Intense competition and pricing pressure within the generic drug manufacturing industry.
- Stringent and evolving regulatory requirements for pharmaceutical products and APIs.
- Potential for R&D failures or delays in obtaining regulatory approvals for new generic drugs.
- Market perception and investor confidence challenges due to its OTC Other tier listing and financial performance.
- Dependence on key strategic alliances and potential risks associated with partnership dynamics.
What Are RXEI's Competitive Advantages?
- Specialization in sterile liquid dose generic drugs, a segment requiring specific manufacturing expertise and regulatory compliance.
- Dual business model encompassing both finished generic drug products and active pharmaceutical ingredient (API) manufacturing services.
- Established strategic alliances with industry partners like Stason Pharmaceuticals, Alkem Laboratories, and Zach Systems S.p.A.
- Diverse and extensive customer base spanning institutional, wholesale, retail, and outpatient healthcare sectors.
- Operating as a subsidiary of Piramal Healthcare Ltd., potentially benefiting from larger corporate resources and stability.
What Does RXEI Do?
RxElite, Inc. is a pharmaceutical company dedicated to the development, production, and commercialization of generic prescription drugs, with a strategic focus on specialty markets. The company's comprehensive product portfolio is centered around Sterile Liquid Dose offerings, which include a range of generic ophthalmic solutions available in both convenient unit-dose and multi-dose formats. Beyond eye care, RxElite also produces sterile unit-dose respiratory inhalation products, addressing critical needs in respiratory health, and various injectable medications vital for institutional healthcare settings. This diverse product array positions RxElite to cater to specific, high-demand segments within the generic pharmaceutical landscape. Operating through its subsidiaries, RxElite extends its capabilities beyond finished drug products by serving as a manufacturer of active pharmaceutical ingredients (APIs). This crucial service supports other pharmaceutical entities across significant global markets, including the United States, Europe, and Asia, highlighting its role in the broader pharmaceutical supply chain. The company's extensive customer base is a testament to its market reach and includes major institutional clients such as hospitals and hospital group purchasing organizations (GPOs), national and regional wholesale distributors, large direct retail pharmacy chains, home healthcare providers, and various outpatient surgery centers and ambulatory care clinics. This broad distribution network ensures its products reach a wide array of healthcare providers and patients. Headquartered in Meridian, Idaho, RxElite Inc. maintains strategic alliances with key industry partners, including Stason Pharmaceuticals, Inc., Alkem Laboratories Limited, and Zach Systems S.p.A. These collaborations are instrumental in enhancing its product development, manufacturing capabilities, and market penetration. As a subsidiary of Piramal Healthcare Ltd., RxElite benefits from the resources and strategic direction of a larger parent organization, further solidifying its operational framework and market presence within the competitive generic drug manufacturing industry.
What Products and Services Does RXEI Offer?
- Develops generic prescription drugs for specialty markets.
- Produces sterile liquid dose ophthalmic solutions in unit-dose and multi-dose formats.
- Manufactures sterile unit-dose respiratory inhalation products.
- Creates various injectable medications for institutional use.
- Serves as a manufacturer of active pharmaceutical ingredients (APIs) for other pharmaceutical companies.
- Distributes products to hospitals, wholesale distributors, retail pharmacies, and outpatient centers.
- Maintains strategic alliances with pharmaceutical partners like Stason, Alkem, and Zach Systems.
- Operates as a subsidiary of Piramal Healthcare Ltd.
How Does RXEI Make Money?
- Research, develop, and commercialize generic prescription drugs, focusing on specialty markets.
- Manufacture and sell a diverse portfolio of sterile liquid dose products, including ophthalmic, respiratory, and injectable medications.
- Provide active pharmaceutical ingredient (API) manufacturing services to other pharmaceutical entities globally.
- Generate revenue through sales to a broad customer base including institutional clients, wholesale distributors, and retail pharmacy chains.
What Industry Does RXEI Operate In?
RxElite, Inc. is positioned within the dynamic and highly competitive Drug Manufacturers - Specialty & Generic industry. This sector is characterized by intense price competition, stringent regulatory oversight, and a continuous need for product development and differentiation. RxElite's specialization in sterile liquid dose offerings, such as generic ophthalmic solutions, respiratory inhalants, and injectables, allows it to target niche markets within the broader generic landscape, where demand for quality and specific delivery formats is high. The company's role as an active pharmaceutical ingredient (API) manufacturer also places it within the critical upstream segment of the pharmaceutical supply chain, serving other drug developers globally. Market trends indicate a growing demand for affordable generic alternatives and a rising need for specialized, sterile formulations, particularly in institutional settings. However, the industry also faces pressures from patent expirations, increasing R&D costs for new generics, and evolving global regulatory standards, requiring companies like RxElite to maintain agility and strategic partnerships to sustain market relevance.
Who Are RXEI's Key Customers?
- Hospitals and hospital group purchasing organizations (GPOs).
- National and regional wholesale distributors.
- Major direct retail pharmacy chains.
- Home healthcare providers.
- Outpatient surgery centers and ambulatory care clinics.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
RxElite, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Meridian, US. The company is led by CEO Richard Tener. RXEI has traded publicly since 2020.
Key Financial Metrics
Return on assets is -80.7%, showing how much profit it generates from its asset base. A current ratio of 2.59 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
RxElite, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.08 places it in the distress zone, a signal of elevated financial risk.
Insider Activity
7 transactions · 0 purchases, 0 sales, 7 other transactions · 2 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
RXEI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
RXEI Latest News
No recent news available for RXEI.
RXEI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RXEI.
Price Targets
Wall Street price target analysis for RXEI.
RXEI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RXEI; grades run from A+ (80-100) to F (below 30).
Leadership: Richard Tener
Chief Executive Officer
Richard Tener serves as a key leader at RxElite, Inc., where he is responsible for managing the company's 47 employees. His role involves overseeing the operational and strategic direction of the pharmaceutical company, which specializes in generic prescription drugs and API manufacturing.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Mr. Tener's leadership are not detailed in the provided information. His tenure is characterized by the ongoing management of RxElite, Inc.'s operations, focusing on the development, production, and commercialization of its diverse portfolio of generic prescription drugs and its active pharmaceutical ingredient manufacturing services.
RXEI OTC Market Information
RxElite, Inc. trades on the 'OTC Other' tier of the over-the-counter market. This tier is typically for companies that do not meet the minimum listing requirements for exchanges like the NYSE or NASDAQ, or even higher OTC tiers like OTCQX or OTCQB. Companies on the 'OTC Other' tier often have limited public disclosure, which can make it challenging for investors to access comprehensive financial and operational information. In contrast, major exchanges impose stringent reporting, governance, and financial standards, offering greater transparency and investor protection. The 'OTC Other' designation generally implies a higher risk profile due to less oversight.
- OTC Tier: OTC Other
- Limited public disclosure and transparency, making comprehensive due diligence challenging.
- Significantly lower trading volume and wider bid-ask spreads, leading to reduced liquidity.
- Increased price volatility due to low trading activity and fewer market participants.
- Potential for limited access to capital markets for financing future operations.
- Negative market perception and investor confidence associated with OTC Other tier listing.
- Verify the availability and content of any financial statements or regulatory filings.
- Thoroughly research the company's business operations, product pipeline, and market position.
- Assess the management team's experience and track record, if available.
- Investigate any legal or regulatory issues the company may be facing.
- Evaluate the company's strategic alliances and their impact on future prospects.
- Understand the competitive landscape within its specific generic drug and API markets.
- Consider the implications of its subsidiary status under Piramal Healthcare Ltd.
- Operating as a subsidiary of Piramal Healthcare Ltd., a larger pharmaceutical entity.
- Maintains strategic alliances with recognized industry partners like Stason Pharmaceuticals and Alkem Laboratories.
- Has a physical headquarters in Meridian, US, and a stated employee count of 47.
- Serves a diverse and established customer base including hospitals, wholesalers, and retail chains.
- Specializes in a tangible and regulated industry: generic prescription drugs and API manufacturing.
Common Questions About RXEI (Healthcare)
What are the key financial characteristics of RxElite, Inc. that investors may want to evaluate?
Investors evaluating RxElite, Inc. should note several key financial characteristics. The company reports a negative profit margin of -610.5%, indicating significant unprofitability. Its gross margin stands at 5.1%, suggesting that after the cost of goods sold, very little revenue remains to cover operating expenses.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is limited to provided source data.
- Specific market sizes, timelines, and detailed financial breakdowns beyond provided metrics are not available in the source data.
- CEO's background and track record details are limited in the source data.